AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12018715
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (1.5 mg/kg/day for 4 weeks)
Trial: 10638398
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DHEM/2% RAMEB nasal spray
Trial: 10638398
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DHEM/4 mg RAMEB nasal powder
Trial: 10638398
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Diergo nasal spray
Trial: 10638398
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DHEM solution p.o.
Trial: 10638398
Drug: i.m. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. administration of 0.5 mg DHEM
Trial: 30672233
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Betastatin mesylate (12 mg, 3 times a day) and mecobalamin (0.5 mg, 3 times a day)
Trial: 30672233
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medication (Betastatin mesylate 12 mg, 3 times a day and mecobalamin 0.5 mg, 3 times a day)
Trial: 23039913
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) group training
Trial: 19830574
Drug: Basal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal therapy
Trial: 16243716
Drug: Enzyme extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme extract (900 mg) in three divided doses
Trial: 16243716
Drug: Enzyme therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme therapy
Trial: 11857598
Drug: 5-aminolaevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-aminolaevulinic acid (ALA) 60 mg/kg BW, oral, 6-8 hours prior to PDT
Trial: 11857598
Drug: Photosan 2
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photosan 2 mg/kg BW, i.v., 48 hours before PDT
Trial: 8520561
Drug: Chemotherapy (ChT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ChT) plus radiotherapy (RT)
Trial: 8520561
Drug: Chemotherapy (ChT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ChT) alone
Trial: 8520561
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who achieved complete response (CR) after treatment
Trial: 2215254
Drug: Aspartame-sweetened beverage
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame-sweetened beverage (600 mg APM per serving)
Trial: 27473440
Drug: Structured lifestyle
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured lifestyle intervention group (IG) with monthly group training sessions and regular telephone contacts.
Trial: 25162191
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (3 weeks, 6 sessions)
Trial: 17482623
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 4 weeks, increasing to 45 mg for 12 weeks
Trial: 16130888
Drug: Taking OTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking OTC medication
Trial: 16130888
Drug: Having a
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Having a family doctor and number of OTC medicines on hand
Trial: 16130888
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more kinds of OTC medicine
Trial: 7272675
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg i.v. preoperatively
Trial: 7272675
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg i.v. preoperatively
Trial: 7272675
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg i.v. postoperatively
Trial: 7272675
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg i.v. preoperatively and 200 mg i.v. daily for 3 days postoperatively
Trial: 24445723
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg + amlodipine 5 mg
Trial: 24445723
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg + amlodipine 5 mg
Trial: 24445723
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + amlodipine 5 mg
Trial: 15781511
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl 50 microg/mL (100 microg)
Trial: 15781511
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 2% (40 mg)
Trial: 10759820
Drug: Hydroquinone 4%
RxNorm normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone 4% cream with 2% glycolic acid applied twice daily for 12 weeks
Trial: 10759820
Drug: Hydroquinone 4%
RxNorm normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone 4% cream with 2% glycolic acid plus salicylic acid peels every 3 weeks
Trial: 1355645
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol xinafoate (50 micrograms)
Trial: 6389973
Drug: Prophylactic antilymphocyte
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antilymphocyte globulin (ALG) treatment for 21 days
Trial: 6389973
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ALG treatment)
Trial: 29589153
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 or 10 mg, once daily orally)
Trial: 29589153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-diabetic drugs other than SGLT-2 inhibitors)
Trial: 16784898
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg daily oral DHEA replacement for one year
Trial: 15725968
Drug: Atomoxetine (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.)
Trial: 15725968
Drug: Atomoxetine (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.8 mg/kg/day)
Trial: 2675432
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Paracetamol
Trial: 26374825
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg administered subcutaneously every 2 weeks
Trial: 12929752
Drug: Intraoperative photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative photodynamic therapy (PDT) using Foscan at a dose of 0.1 mg/kg 6 days before surgery and 652 nm red light at a dose of 10 J/cm2
Trial: 11044498
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with medroxyprogesterone acetate
Trial: 11044498
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with danazol
Trial: 11044498
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with nafarelin
Trial: 11044498
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy after surgical treatment
Trial: 8970686
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day oxandrolone
Trial: 8970686
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day oxandrolone
Trial: 1483989
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily
Trial: 3883235
Drug: Clonidine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.125 to 0.3 mg/d)
Trial: 28546367
Drug: Intensive PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive PD dosage (> 30 L per day)
Trial: 28546367
Drug: Minimal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal standard PD dosage (< 20 L per day)
Trial: 19843056
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol clamping to maintain a pseudo-steady-state BrAC of 0.6 g l(‐1)
Trial: 17854250
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER (75 to 300 mg/day)
Trial: 9544380
Drug: Bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate one tablet qid, tetracycline 500 mg qid and metronidazole 400 mg tds (BTM)
Trial: 9544380
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bd, amoxycillin 500 mg qid and metronidazole 400 mg tds (LAM)
Trial: 2462264
Drug: 3 times/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times/week at 2 Gy/day twice a day at a minimum interval of 6 h for a total of 20 Gy/10 fractions (Group III)
Trial: 28651151
Drug: IVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR with weekly schedule
Trial: 28651151
Drug: IVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR with daily schedule
Trial: 28651151
Drug: SMS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS with weekly schedule
Trial: 28651151
Drug: SMS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS with daily schedule
Trial: 28651151
Drug: IVR (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR (daily and weekly)
Trial: 28651151
Drug: SMS (weekly)
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS (weekly)
Trial: 23759267
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 11% pea protein hydrolysate and 89% carbohydrates (79% maltodextrin and 21% sucrose), 400 mL the night before and 200 mL 3 h before surgery
Trial: 11106122
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of eniluracil (20 mg) and 5-FU (2 mg)
Trial: 11106122
Drug: Combined eniluracil/5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined eniluracil/5-FU tablets (10/1 mg)
Trial: 11106122
Drug: Combined eniluracil/5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined eniluracil/5-FU tablets (2.5/0.25 mg)
Trial: 8279247
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion for 25 min and thereafter isoflurane (Group B)
Trial: 8279247
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion throughout the procedure (Group C)
Trial: 2876923
Drug: Tulobuterol 30
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol 30 mcg/kg twice daily
Trial: 2876923
Drug: Terbutaline 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 75 mcg/kg three times daily
Trial: 2876923
Drug: Tulobuterol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol (various doses 10 to 60 mcg/kg)
Trial: 2876923
Drug: Tulobuterol 30
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol 30 and 40 mcg/kg twice daily
Trial: 22633722
Drug: Intravenous contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous contrast alone (IV)
Trial: 22633722
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral contrast (IVO)
Trial: 18546896
Drug: Propofol (PRO)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (PRO) 1‐3 mg x kg(‐1) x hr(‐1)
Trial: 15802769
Drug: Bisphosphonates (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (long-term treatment)
Trial: 10621536
Drug: Human amniotic
RxNorm normalized name: Human Amniotic Fluid
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human amniotic membrane adjunct use
Trial: 8803365
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss treatment (21.1 +/- 8.4 kg lost after 6 months)
Trial: 6123837
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days)
Trial: 30977398
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly group sessions of manualized memory rehabilitation plus usual care
Trial: 28535810
Drug: bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 400 mg qid for 21 days
Trial: 25495359
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (ET)
Trial: 17901953
Drug: PF (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF (cisplatin 100 mg/m² i.v. Day 1 and 5-FU 1,000 mg/m² per day i.v. continuous infusion D1-D5, every 21 days)
Trial: 17901953
Drug: UFTVP (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFTVP (cisplatin 100 mg/m² i.v. Day 1; UFT 200 mg/m² per day p.o. D1-D21 and vinorelbine 25 mg/m² i.v. D1 and D8, every 21 days)
Trial: 10463173
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with two acellular and one whole-cell pertussis vaccine
Trial: 10463173
Drug: B. pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. pertussis strains used in vaccines
Trial: 7841012
Drug: Caries Meter
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caries Meter L
Trial: 29440016
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of POC CRP and BISNA
Trial: 20217230
Drug: Forensic assertive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forensic assertive community treatment (FACT)
Trial: 12086199
Drug: Flunisolide HFA
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide HFA (340 microg daily)
Trial: 12086199
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (6400 microg daily)
Trial: 12086199
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) (336 microg daily)
Trial: 10429772
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol and dolasetron (10 micrograms x kg‐1 + 12.5 mg)
Trial: 7593515
Drug: Microlaparoscope <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microlaparoscope < 2.0 mm diameter under analgesic sedation plus local anaesthesia (group II)
Trial: 2105990
Drug: Budesonide aerosol
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aerosol (4 weeks treatment)
Trial: 25719620
Drug: Paravertebral blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral blocks (PVB) and total intravenous anesthesia
Trial: 25719620
Drug: Sham subcutaneous
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham subcutaneous injections and standardized general anesthesia
Trial: 8591720
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 14C-labeled meloxicam (intravenous infusion)
Trial: 8591720
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 14C-labeled meloxicam (oral solution)
Trial: 2649022
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (20 ml containing 9% gamma-linolenic acid)
Trial: 14577658
Drug: CLA supplementation
RxNorm normalized name: CLA
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLA supplementation (2.1 g daily for 45 days)
Trial: 8923023
Drug: Supplements of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements of vitamins (with or without other antioxidants)
Trial: 1738797
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of theophylline (400 mg)
Trial: 1738797
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of theophylline (300 mg b.d. for 4 weeks)
Trial: 6395773
Drug: Prednisolone 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.75 mg/kg/day
Trial: 6395773
Drug: Prednisolone 1.25
RxNorm normalized name: prednisolone 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1.25 mg/kg/day
Trial: 30736773
Drug: Additional periarticular
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional periarticular injection (40 mg methylprednisolone, 150 mg ropivacaine, 0.1 mg epinephrine)
Trial: 30736773
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional injection
Trial: 29248359
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa enzyme replacement therapy (ERT), administered weekly for 96 weeks.
Trial: 29248359
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa ERT (continuously treated patients), administered weekly for 96 weeks.
Trial: 17205319
Drug: Risperidone 1
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1 mg
Trial: 18444492
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) - 3x2 injections into both nasal cavities for 4 weeks
Trial: 18444492
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - intranasal physiologic saline
Trial: 17294999
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of 0.9% sodium chloride (control group)
Trial: 7930473
Drug: Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2b with prednisolone in decreasing doses of 60, 40, 20 mg for 6 weeks
Trial: 3332914
Drug: ciladopa 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciladopa 15 mg b.i.d.
Trial: 3332914
Drug: ciladopa 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciladopa 5 mg b.i.d.
Trial: 29860362
Drug: Social modeling
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social modeling of side effects (placebo treatment)